Search results for "Chickenpox"

showing 7 items of 27 documents

A combination vaccine against measles, mumps, rubella and varicella.

2008

A new combination vaccine against measles, mumps, rubella and varicella (MMRV) from GlaxoSmithKline Biologicals has recently been approved in Europe. It combines the components from two well-established, live, attenuated vaccines against measles, mumps and rubella. This review presents a summary of the development of this MMRV vaccine from published clinical studies. Seroconversion rates and antibody titers after the first and second dose are similar to those observed after concomitant administration of the MMR and varicella vaccines. Furthermore, the clinical profile of this combination vaccine, in terms of injection- site and general tolerability, is similar to that of the component vacci…

Pediatricsmedicine.medical_specialtymedicine.vaccineMeaslesRubellaChickenpox VaccineChickenpoxmedicineHumansPharmacology (medical)Vaccines CombinedSeroconversionChildMumpsImmunization ScheduleRubellaPharmacologyAttenuated vaccineMMRV vaccinebusiness.industryVaccinationAntibody titerInfantGeneral Medicinemedicine.diseaseVirologyVaccinationTolerabilityChild PreschoolbusinessMeasles-Mumps-Rubella VaccineMeaslesDrugs of today (Barcelona, Spain : 1998)
researchProduct

Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalen…

2020

Abstract Background We assessed the 10-year efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine (MMRV) or one dose of a monovalent varicella vaccine (V) in children from Czech Republic, Lithuania, Poland, Romania and Slovakia. Methods This was a phase IIIB follow-up of an observer-blind, randomized, controlled trial (NCT00226499). In phase A, healthy children aged 12–22 months from 10 European countries were randomized in a 3:3:1 ratio to receive two doses of MMRV (MMRV group), one dose of MMR followed by one dose of V (MMR + V group), or two doses of MMR (MMR; control group), 42 days apart. Vaccine efficacy (VE) against varicella (confirme…

Slovakiamedicine.medical_specialtyVaricella vaccineAntibodies Viralmedicine.disease_causelaw.inventionChickenpox Vaccine03 medical and health sciences0302 clinical medicineRandomized controlled triallaw030225 pediatricsInternal medicineEpidemiologymedicineHumansVaccines Combined030212 general & internal medicineChildAdverse effectMumpsRubellaCzech RepublicGeneral VeterinaryGeneral Immunology and MicrobiologyRomaniabusiness.industryImmunogenicityPublic Health Environmental and Occupational HealthVaricella zoster virusInfantVaccine efficacyConfidence intervalEuropeInfectious DiseasesMolecular MedicinePolandbusinesschildren ; efficacy ; live-attenuated varicella vaccine ; long-term follow-up ; measles-mumps-rubella ; varicella zoster virusMeasles-Mumps-Rubella VaccineFollow-Up StudiesMeaslesVaccine
researchProduct

A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra: immunogenicity and safety profile

2009

Abstract Priorix-Tetra ™ (GlaxoSmithKline Biologicals) is a combined measles, mumps, rubella and varicella (MMRV) vaccine. Eight studies involving more than 3000 children were reviewed. Compared with co-administration of MMR ( Priorix ™) and varicella ( Varilrix ™) vaccines, the MMRV vaccine showed: similar immunogenicity, with immunity shown up to 3 years post-vaccination; a higher rate of fever after the first dose; a slight increase in mild local reactions after the second dose. This MMRV vaccine can be used either as a two-dose vaccine or as a second dose in children primed with separate MMR and/or varicella vaccines, offering a convenient way to introduce varicella vaccination into rou…

Varicella vaccineImmunization Secondarymedicine.vaccineAntibodies ViralRubellaMeaslesChickenpox VaccinemedicineHumansVaccines CombinedChildClinical Trials as TopicReactogenicityMMRV vaccineGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityPublic Health Environmental and Occupational HealthInfantvirus diseasesmedicine.diseaseVirologyVaccinationInfectious DiseasesImmunizationChild PreschoolMolecular MedicinebusinessMeasles-Mumps-Rubella Vaccine
researchProduct

MMR and MMRV vaccines.

2018

Measles, mumps, rubella and varicella are viral infections which can implicate seriously long-term sequelae of infected individuals or even the unborn child. Vaccines against the individual diseases have long been available. Global measles vaccination is estimated to have prevented more than 20million deaths during 2000-2015. During the same time period, measles incidence decreased from 146 to 36 cases per million populations. Today vaccinations against measles, mumps, rubella and varicella are now carried out mainly with combination vaccines. These are today known as immunogenic and safe. MMRV had similar immunogenicity and overall safety profiles to MMR administered with or without varice…

Varicella vaccineRubellaMeasles03 medical and health sciences0302 clinical medicineChickenpox030225 pediatricsmedicineHumans030212 general & internal medicineAdverse effectMumpsRubellaVaccinesGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityIncidence (epidemiology)VaccinationPublic Health Environmental and Occupational Healthvirus diseasesmedicine.diseaseVaccinationInfectious DiseasesImmunizationImmunologyMolecular MedicinebusinessMeaslesVaccine
researchProduct

Reducing the burden of Herpes Zoster in Italy.

2015

Herpes Zoster (HZ) is a viral disease with painful neuro-dermatologic manifestations. Incidence increases with age. In Italy, the estimated incidence is 6.3 cases/1000 person/year; hospital admissions are less than 2%, 69% in patients aged over 65 years. The most frequent complication of HZ is Post-Herpetic Neuralgia (PHN) characterized by metameric pain, allodynia, and hyperalgesia. In Italy 20.6% and 9.2% of HZ patients experience PHN after 3 and 6 months, respectively. Available antiviral and analgesic treatments are relatively unsatisfactory in reducing pain and length of the disease. Prevention has recently become possible with the live attenuated vaccine Oka/Merck. Clinical studies sh…

medicine.medical_specialtyPediatricsHerpes Zoster epidemiology burden prevention immunizationSettore MED/17 - Malattie InfettiveCost-Benefit AnalysisImmunologyNeuralgia PostherpeticDiseaseSettore MED/42 - Igiene Generale E ApplicataimmunizationHerpes ZosterHerpes Zoster; epidemiology; burden; prevention; immunizationburdenChickenpox VaccinepreventionEpidemiologymedicineHumansImmunology and AllergyChickenpox VaccinePharmacologyHerpes Zoster; burden; epidemiology; immunization; preventionbusiness.industryIncidenceIncidence (epidemiology)medicine.diseaseSurgeryVaccinationAllodyniaItalyNeuralgiaepidemiologyViral diseasemedicine.symptombusinessResearch Paper
researchProduct

Evaluation of varicella vaccine effectiveness as public health tool for increasing scientific evidence and improving vaccination programs

2020

Brazil; Chickenpox Vaccine; Humans; Immunization Programs; Public Health; Vaccination; Chickenpox; Viral Vaccines.

medicine.medical_specialtyVaricella vaccineMEDLINESettore MED/42 - Igiene Generale E ApplicataScientific evidenceChickenpox VaccineChickenpoxmedicineHumansChickenpox VaccineViral Vaccines.Immunization Programsbusiness.industryImmunization ProgramPublic healthViral VaccineVaccinationlcsh:RJ1-570Viral Vaccineslcsh:PediatricsVaccinationFamily medicinePediatrics Perinatology and Child HealthPublic HealthbusinessBrazilHumanJornal de Pediatria
researchProduct

Herpes zóster posvacunal: valor del citodiagnóstico de Tzank

2016

medicine.medical_specialtybusiness.industryTolonium chlorideDiagnostico diferencialColoring agentsDermatologyPediatricsRJ1-570030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicinechemistry030225 pediatricsPediatrics Perinatology and Child HealthmedicinebusinessChickenpox VaccineAnales de Pediatría
researchProduct